NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Prospective Observational Study of Filgotinib in Subjects With Rheumatoid Arthritis

NCT04871919

Active Not RecruitingN/A

Sponsor: Alfasigma S.p.A.

Conditions: Rheumatoid Arthritis

Interventions: Filgotinib

Countries: Belgium, Germany, Italy, Netherlands, Spain, United Kingdom

An observational study to describe the effectiveness, safety, and patient-reported outcomes in patients with moderate to severe active rheumatoid arthritis (RA) receiving filgotinib in real-world setting.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Patients aged ≥ 18 years with a diagnosis of moderate to severe active RA being prescribed filgotinib in accordance with the local standard of care and product label for the first time.
* Patients must be willing and able to use an electronic device to complete the study patient-reported outcome (PRO).

Exclusion Criteria:

\- Participation in any other interventional or non-interventional study without prior approval from the Medical Monitor. This does not preclude inclusion of patients enrolled to national registries.

Locations (89)

Aalst, Belgium
Bonheiden, Belgium
Bruges, Belgium
Brussels, Belgium
Brussels, Belgium
Charleroi, Belgium
Edegem, Belgium
Genk, Belgium
Genk, Belgium
Ghent, Belgium
Hasselt, Belgium
Leuven, Belgium
Liège, Belgium
Merksem, Belgium
Yvoir, Belgium
Altenburg, Germany
Amberg, Germany
Bad Doberan, Germany
Berlin, Germany
Berlin, Germany
Berlin, Germany
Berlin, Germany
Demmin, Germany
Dresden, Germany
Düsseldorf, Germany
Ehringshausen, Germany
Erfurt, Germany
Greifswald, Germany
Halle, Germany
Hamburg, Germany
+ 59 more on CT.gov